JPMorgan Chase & Co. Sells 104,750 Shares of OptimizeRx Co. (NASDAQ:OPRX)

JPMorgan Chase & Co. reduced its position in shares of OptimizeRx Co. (NASDAQ:OPRX) by 93.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,783 shares of the company’s stock after selling 104,750 shares during the period. JPMorgan Chase & Co.’s holdings in OptimizeRx were worth $60,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the period. Quest Partners LLC boosted its position in shares of OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. Barclays PLC boosted its stake in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. Squarepoint Ops LLC acquired a new position in OptimizeRx during the 2nd quarter valued at about $282,000. Finally, Marshall Wace LLP bought a new position in shares of OptimizeRx during the 2nd quarter worth approximately $457,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OPRX. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th. Roth Mkm reissued a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective for the company. B. Riley decreased their price target on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Finally, Barclays cut their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.06.

Insiders Place Their Bets

In other news, CEO William J. Febbo acquired 20,000 shares of OptimizeRx stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. The trade was a 3.44 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 6.10% of the company’s stock.

OptimizeRx Stock Up 3.2 %

OPRX opened at $5.73 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $16.65. The company has a market capitalization of $105.55 million, a PE ratio of -4.31 and a beta of 1.36. The firm’s 50 day simple moving average is $5.22 and its two-hundred day simple moving average is $6.63.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.